Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Dianthus Therapeutics (DNTH) Return on Sales (2022 - 2025)

Dianthus Therapeutics has reported Return on Sales over the past 4 years, most recently at 98.34% for Q3 2025.

  • Quarterly results put Return on Sales at 98.34% for Q3 2025, down 8554.0% from a year ago — trailing twelve months through Sep 2025 was 41.42% (down 2767.0% YoY), and the annual figure for FY2024 was 13.55%, up 181.0%.
  • Return on Sales for Q3 2025 was 98.34% at Dianthus Therapeutics, up from 178.87% in the prior quarter.
  • Over the last five years, Return on Sales for DNTH hit a ceiling of 24.36% in Q4 2022 and a floor of 178.87% in Q2 2025.
  • Median Return on Sales over the past 4 years was 15.94% (2023), compared with a mean of 31.23%.
  • Biggest five-year swings in Return on Sales: soared 1186bps in 2024 and later tumbled -16925bps in 2025.
  • Dianthus Therapeutics' Return on Sales stood at 24.36% in 2022, then plummeted by -225bps to 30.45% in 2023, then skyrocketed by 39bps to 18.59% in 2024, then crashed by -429bps to 98.34% in 2025.
  • The last three reported values for Return on Sales were 98.34% (Q3 2025), 178.87% (Q2 2025), and 25.27% (Q1 2025) per Business Quant data.